Our findings also suggest that rosiglitazone, a clinically approved antidiabetic drug, may be useful for the treatment of vasculopathies that are caused by increased TGFβ signaling, e.g. Marfan syndrome, as well as for the supportive treatment of certain malignancies, such as malignant glioblastomas [43]. Here, TGFB1 is linked to Marfan syndrome.